Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Case report

Actinomycetoma in SE Asia: the first case from Laos and a review of the literature

Sayaphet Rattanavong1, Sivay Vongthongchit2, Khamhou Bounphamala2, Phouvong Vongphakdy3, Jacques Gubler4, Mayfong Mayxay156, Rattanaphone Phetsouvanh16, Ivo Elliott16, Julie Logan7, Robert Hill8, Paul N Newton16 and David Dance16*

Author Affiliations

1 Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR

2 Surgery Unit, Xiengkhuang Provincial Hospital, Xiengkhuang, Lao PDR

3 General Surgery Department, Mahosot Hospital, Vientiane, Lao PDR

4 Department of Medicine, Infectious Diseases, Kantonsspital, Winterthur, Switzerland

5 Faculty of Postgraduate Studies, University of Health Sciences, Vientiane, Lao PDR

6 Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK

7 Department for Bioanalysis and Horizon Technologies, Health Protection Agency Microbiology Services Colindale, 61 Colindale Avenue, London, NW9 5HT, UK

8 Antibiotic Resistance Monitoring & Reference Laboratory (ARMRL), Health Protection Agency Microbiology Services Colindale, 61 Colindale Avenue, London, NW9 5EQ, UK

For all author emails, please log on.

BMC Infectious Diseases 2012, 12:349  doi:10.1186/1471-2334-12-349


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2334/12/349


Received:15 August 2012
Accepted:10 December 2012
Published:12 December 2012

© 2012 Rattanavong et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Mycetoma is a chronic, localized, slowly progressing infection of the cutaneous and subcutaneous tissues caused either by fungi (eumycetoma or implantation mycosis) or by aerobic actinomycetes (actinomycetoma). It is acquired by traumatic implantation, most commonly in the tropics and subtropics, especially in rural agricultural communities. Although well recognized elsewhere in Asia, it has not been reported from the Lao People’s Democratic Republic (Laos).

Case presentation

A 30 year-old female elementary school teacher and rice farmer from northeast Laos was admitted to Mahosot Hospital, Vientiane, with a massive growth on her left foot, without a history of trauma. The swelling had progressed slowly but painlessly over 5 years and multiple draining sinuses had developed. Ten days before admission the foot had increased considerably in size and became very painful, with multiple sinuses and discharge, preventing her from walking. Gram stain and bacterial culture of tissue biopsies revealed a branching filamentous Gram-positive bacterium that was subsequently identified as Actinomadura madurae by 16S rRNA gene amplification and sequencing. She was treated with long-term co-trimoxazole and multiple 3-week cycles of amikacin with a good therapeutic response.

Conclusion

We report the first patient with actinomycetoma from Laos. The disease should be considered in the differential diagnosis of chronic skin and bone infections in patients from rural SE Asia.

Keywords:
Mycetoma; Madura foot; Actinomadura madurae; Lao PDR; Laos; Southeast Asia

Background

Mycetoma, commonly known as Madura foot, is a chronic, localized, slowly progressive, granulomatous infection of the deep dermis and subcutaneous tissue caused either by fungi (eumycetoma or implantation mycosis) or by aerobic actinomycetes (actinomycetoma) [1]. It was first described in India by Gill in 1842 and the term mycetoma was first used by Carter in 1860 [1,2]. Mycetoma occurs unevenly worldwide but is endemic in tropical and sub-tropical regions, particularly between latitudes 15° S and 30° N, known as the ‘Mycetoma belt’. The belt includes Sudan, Somalia, Senegal, India, Yemen, Mexico, Venezuela, Colombia and Argentina. In Sudan, 1231 cases were reported within a 2.5-year period and it was found to be the third commonest cause of amputation [3,4]. Cases imported from endemic areas are occasionally seen in temperate countries [5].

More than 20 species of bacteria and fungi have been identified as aetiologic agents of mycetoma: approximately 60% of cases are due to bacteria and 40% are caused by fungi. The predominant cause varies geographically, probably because of environmental factors [6]. In India, Mexico and Brazil, actinomycetoma is the most common but in Sudan most cases are implantation mycoses. The agents most often responsible for causing actinomycetoma are Actinomadura madurae, Actinomadura pelletieri, Nocardia brasiliensis and Streptomyces somaliensis. Madurella mycetomatis, M. grisea and Pseudallescheria boydii are the most common causes of implantation mycoses [7-11]. Actinomycetoma tends to progress more rapidly, with greater inflammation and tissue destruction and earlier invasion of bone than implantation mycosis. Initially, the patient may feel pain or discomfort at the inoculated site. After traumatic inoculation, painless subcutaneous nodules slowly develop and spread. Later, the nodules increase in size and quantity with accompanying sinuses that drain serous, sero-sanguineous or purulent fluid [12]. The main route of infection is uncertain but, as organisms are usually present in the soil [13], it is likely that they are implanted into the host tissue by traumatic inoculation such as thorn pricks or splinters, although only half of the patients can remember a history of trauma preceding the disease [7]. This theory is supported by the facts that cases are common among farmers, herdsmen, field labourers or people walking bare foot and that the main affected areas are foot and hand, although other parts may be involved less frequently [12,14-16]. The incubation period is variable, from three months to nine years in natural infections. Since the mean duration before the first medical evaluation is five years, patient recall of trauma may often be unreliable [7,17].

Mycetoma is more common in males than females, with an overall sex ratio of 3:1, possibly relating to differences in occupational and other outdoor activities rather than gender differences in susceptibility [11,15]. The condition is also commonest in young adults (16–40 years old) [9].

Irrespective of the causative agent, the clinical presentation is similar, with tissue swelling and draining sinuses that usually discharge visible grains. It is important to determine the causative agent of mycetoma in order to choose the appropriate treatment. The colour of the grains in the discharge from the sinuses may be helpful for presumptive identification of the aetiology, although this is not entirely reliable. Black grains are said to be associated with Madurella mycetomatis, Madurella grisea, Exophiala jeanselmei, Curvularia species, Leptosphaeria species and Pyrenochaeta species, white grains with Nocardia species, Actinomadura madurae, Pseudallescheria boydii, Acremonium species, Cylindrocarpon species and Fusarium species, yellow grains with Streptomyces somaliensis and red with Actinomadura pelletieri[3,14]. Differential diagnosis includes soft tissue tumours such as lipoma, fibroma, sarcoma, malignant melanoma and chronic osteomyelitis caused by pyogenic bacteria or mycobacteria, and other mycoses such as chromoblastomycosis, lobomycosis, paracoccidioidomycosis, phaeohyphomycosis and sporotrichosis [18].

Although cases have been reported from neighbouring countries, mycetoma has never been reported in Laos: we report here the first case.

Case presentation

An otherwise healthy 30-year-old female elementary school teacher and rice farmer from Namun village (19.6552435·° N, 103.5781784·° E), Kham District, Xiengkhuang Province, northeast Laos, presented to Mahosot Hospital in October 2011 with tumefaction, pain and multiple draining sinuses on her left foot. The lesion had started 5 years previously, initially with an uncomfortable feeling and itching on the left plantar surface that over a few days became indurated and developed a spontaneously draining sinus. She remembered no specific injury to her foot. Over the next five years, the lesion slowly and painlessly progressed, with swelling and multiple draining sinuses. Ten days before admission she developed acute swelling of the foot with severe pain associated with multiple sinuses and discharge from the foot that prevented her from walking. Foot X-ray done at a local hospital showed signs of osteolysis of the left metatarsal bones. With a diagnosis of chronic osteomyelitis of the left foot she was treated with oral cloxacillin for a few days, but when branching Gram positive rods were demonstrated on a Gram stain of an aspirate from the lesion at the provincial hospital she was transferred to Mahosot Hospital. On examination, she was orientated, afebrile with normal vital signs, and physical examination was unremarkable except for a massive tumour-like lesion of the left foot with multiple sinuses on the dorsal and plantar surfaces. The overlying skin was moderately erythematous and was tender and painful on palpation with evidence of a sero-sanguinous discharge containing no obvious grains (Figures 1 and 2). There was no regional lymphadenopathy or lymphangitis present. Admission laboratory investigation (normal ranges in parentheses) revealed a total white blood cell count of 6.1 × 109/L (6.0-8.0 × 109/L), 68% neutrophils (45-70%), haematocrit 28% (37-47%), haemoglobin 75 g/L (120–160 g/L), mean corpuscular volume 59 fL (80-95fL), platelets 449 × 109/L (150-300 × 109/L), creatinine 72 μmol/L (53-120 μmol/L), urea 4.3 mmol/L (5.3-16 mmol/L), aspartate transaminase 50 U/L (0–37 U/L), alanine transaminase 34 U/L (0–45 U/L) and blood glucose 4.2 mmol/L (4.1- 6.4 mmol/L). A radiograph of the left foot confirmed partial osteolysis of the metatarsal bones (Figure 3). Four 3 mm diameter tissue biopsies were taken from her left foot under local anaesthesia. Smears from these samples underwent microscopy after Gram stain, Ziehl-Neelsen stain and the 20% potassium hydroxide technique. The samples were cultured aerobically on blood, chocolate, MacConkey, Sabouraud and Ashdown’s agars and were submitted for mycobacterial culture and histopathology. The Gram stain revealed scanty branching filamentous Gram positive bacteria (Figure 4), which grew after 5 days’ incubation on chocolate and blood agar. She was presumptively diagnosed as suffering from actinomycetoma and started on amikacin (15 mg/kg/day) combined with trimethoprim-sulfamethoxazole (7/35 mg/kg/day), both in two daily doses. One biopsy sample, which had been immediately frozen at −80°C, and the organism were both identified by 16S rRNA amplification and sequencing as Actinomadura madurae (Figure 5) by the Health Protection Agency (HPA), UK [19]. Broth dilution MICs for the organism, performed by the HPA, gave the following results (mg/l): amikacin ≤ 0.25 (S), gentamicin 2 (S), tobramycin ≤ 0.25 (S), amoxicillin/clavulanate 4 (S), cefotaxime 4, ceftriaxone 0.25 (S), imipenem ≤ 0.125 (S), meropenem 0.5 (S), co-trimoxazole 0.032 (S), clarithromycin 4 (I), ciprofloxacin ≤ 0.25 (S), moxifloxacin ≤ 0.25 (S) and doxycycline ≤ 0.25 (S). After 21 days of intravenous amikacin and oral trimethoprim-sulfamethoxazole, the patient’s left foot showed some evidence of healing with decreasing pain, swelling and discharge without any side effects from treatment. She was transferred for further treatment at a district hospital close to her home. On the basis of published recommendations, amikacin was given for sequential cycles of 3 weeks with 2 week breaks, and trimethoprim-sulfamethoxazole was continued throughout: creatinine and hearing were monitored weekly without abnormalities [20,21]. After 5 cycles of treatment there had been a marked reduction in swelling (Figures 6 and 7), considerable symptomatic improvement, and the patient was able to walk and to return to teaching. The patient continued on oral co-trimoxazole alone until a total of 12 months of treatment had been completed, at which stage she had no pain at rest and there were no sinuses or discharge from the foot, although there was still considerable residual bony abnormality evident radiologically (Figure 8).

thumbnailFigure 1. Left foot of the patient showing classic features of mycetoma: tumefaction, sinus tracts and discharge.

thumbnailFigure 2. Left foot of the patient showing classic features of mycetoma: tumefaction, sinus tracts and discharge.

thumbnailFigure 3. X-ray of the left foot showing sign of destruction of the metatarsal bones.

thumbnailFigure 4. Gram stain of smear from left foot tissue biopsy revealed branching, filamentous Gram positive bacteria.

thumbnailFigure 5. Unrooted tree of Actinomadura spp. partial 16S rRNA sequences (bases ~1200 bp, accession numbers after species name).

thumbnailFigure 6. Left foot of the patient after 5 cycles of amikacin showing considerable resolution of swelling and healing of sinus tracts.

thumbnailFigure 7. Left foot of the patient after 5 cycles of amikacin showing considerable resolution of swelling and healing of sinus tracts.

thumbnailFigure 8. X-ray of the left foot after 1 year of treatment showing considerable residual bony abnormalities.

Our patient represents a fairly typical, albeit severe, case of actinomycetoma caused by A. madurae, with involvement of the underlying bone. Bone involvement is common in advanced stages of the disease (an incidence of 73% was reported in one series), leading to deformity and disability of the affected area [22].

Even a classic clinical presentation and typical colours of grains in mycetoma does not reliably distinguish actinomycetoma from implantation mycosis, so laboratory investigations, including microscopy, histology and extended cultures are indicated. Other investigations including fine needle aspiration cytology, imaging (X-ray, magnetic resonance and ultrasound), sero-diagnosis (counter-immunoelectrophoresis and ELISA) and molecular detection and identification may also be useful [14,18]. Although the evidence base is poor, without clinical trials, combined treatment with multiple antibiotics is usually recommended in order to prevent drug resistance and eradicate any residual infection. Reported cure rates vary widely ranging from 60% to 90%. Sulphonamides and sulphonamide combinations are recommended as the first line treatment. Aminoglycosides, tetracyclines, rifampicin, ciprofloxacin and amoxicillin-clavulanate have also been used successfully. The combination of amikacin and co-trimoxazole, the former given in cycles, has produced excellent clinical results, especially in those at risk of pulmonary spread or vertebral involvement [21]. Five to ten cycles may be needed to achieve cure. Furthermore, surgery may be considered for small lesions, infections that fail to respond to antibiotics and to help medical treatment by reduction of the infective load or deal with life-threatening lesions [12,14,18,20].

This is the first case of mycetoma reported from Laos. Cases have been reported infrequently from Southeast Asia, the majority of which has a prolonged rainy season unlike the arid regions usually associated with mycetoma. Mycetoma has, however, been reported from Singapore, Malaysia, Philippines, Indonesia, Cambodia, Thailand and Vietnam. Table 1 shows cases identified by searching PubMed using the terms ‘Mycetoma’ AND ‘Southeast Asia’ or ‘Mycetoma’ AND the names of individual countries (‘Lao’, ‘Thai’, ‘Cambodia’, ‘Burma’, ‘Myanmar’, ‘Malaysia’, ‘Singapore’, ‘Indo’, ‘Philip’, ‘Timor’, ‘Brunei’, ‘Vietnam’). The true incidence in the region, however, is unknown.

Table 1. Summary of reports of Mycetoma in Southeast Asia

Conclusions

This patient confirms the existence of mycetoma caused by Actinomadura madurae in Laos. Approximately 78% of the Lao population works mainly in agriculture and there are, as elsewhere in the rural tropics, few microbiology laboratories, making it likely that the condition is under-diagnosed. Isolation of the causative organism enabled medical treatment, which almost certainly saved this young woman from amputation and lifelong disability. Mycetoma should be considered in the differential diagnosis of chronic skin and bone infections in Laos and elsewhere in Southeast Asia.

Consent

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review from the Series Editor of this journal.

Competing interests

All authors declare that they have no competing interest.

Authors’ contributions

SR wrote the manuscript with DD, who made the laboratory diagnosis. JG, KB and SV made the initial clinical diagnosis and referred the patient for further management. SR, SV, IE, MM, RP, PN and DD helped with patient management. JL identified the organism by 16S rRNA amplification and sequencing and RH undertook the susceptibility testing. All authors were involved in revising the manuscript and approved the final version.

Acknowledgements

We are grateful to the patient and all the staff of the Microbiology Laboratory and surgeons and nurses of the Surgery Ward, Mahosot Hospital, Vientiane, Laos, and to the Minister of Health and the Director of the Curative Department, Ministry of Health, for their support. This work was part of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit funded by the Wellcome Trust of Great Britain.

References

  1. Fahal AH, Hassan MA: Mycetoma.

    Br J Surg 1992, 79:1138-1141. PubMed Abstract | Publisher Full Text OpenURL

  2. Muttardi NE, Kulendren D, Jemec B: Madura foot-mind the soil.

    J Plast Reconstr Aesthet Surg 2010, 63:e576-e578. PubMed Abstract | Publisher Full Text OpenURL

  3. Ahmed AOA, Leeuwen WV, Fahal A, Sande WV, Verbrugh H, Belkum AV: Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.

    Lancet Infect Dis 2004, 4:566-574. PubMed Abstract | Publisher Full Text OpenURL

  4. Shaheen SM: Patients with lower limb amputations for mycetoma in the National Center for Prosthetics and Orthotics in the Sudan.

    Khartoum Med J 2008, 1:27-29. OpenURL

  5. Hay RJ, Mackenzie DWR: Mycetoma (Madura foot) in the United Kingdom-a survey of forty-four cases.

    Clin Exp Dermatol 1983, 8:553-562. PubMed Abstract | Publisher Full Text OpenURL

  6. Welsh O, Vera-Cabrera L, Salinas-Carmona MC: Mycetoma.

    Clin Dermatol 2007, 25:195-202. PubMed Abstract | Publisher Full Text OpenURL

  7. Maiti PK, Ray A, Bandyopadhyay S: Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal.

    Trop Med Int Health 2002, 7:788-792. PubMed Abstract | Publisher Full Text OpenURL

  8. Papaioannides D, Akritidis NK: Painless foot swelling with a chronic purulent discharge.

    West J Med 2001, 174:96-97. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  9. López Martínez R, Méndez Tovar LJ, Lavalle P, Welsh O, Saúl A, Macotela Ruíz E: Epidemiology of mycetoma in Mexico: study of 2105 cases.

    Gac Med Mex 1992, 128:477-481. PubMed Abstract OpenURL

  10. Castro LG, Belda Júnior W, Salebian A, Cucé LC: Mycetoma: a retrospective study of 41 cases seen in Sao Paulo, Brazil, from 1978 to 1989.

    Mycoses 1993, 36:89-95. PubMed Abstract OpenURL

  11. Fahal AH, Abu Sabaa AH: Mycetoma in children in Sudan.

    Trans R Soc Trop Med Hyg 2010, 104:117-121. PubMed Abstract | Publisher Full Text OpenURL

  12. Fahal AH: Mycetoma: a thorn in the flesh.

    Trans R Soc Trop Med Hyg 2004, 98:3-11. PubMed Abstract | Publisher Full Text OpenURL

  13. Aghamirian MR, Ghiasian SA: Isolation and characterization of medically important aerobic Actinomycetes in soil of Iran (2006–2007).

    Open Microbiol J 2009, 3:53-57. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  14. Fahal AH: Mycetoma.

    Khartoum Med J 2011, 4:514-523. OpenURL

  15. Hashemi SJ, Nasrollahi A, Guerami M, Daei R, Pakshir K, Zibafar A: Mycetoma in Iran: study of 62 cases.

    Asian J Epidemiol 2008, 1:77-81. Publisher Full Text OpenURL

  16. Tilak R, Singh S, Garg A, Bassi J, Tilak V, Gulati AK: A case of Actinomycotic mycetoma involving the right foot.

    J Infect Developing Countries 2009, 3:71-73. OpenURL

  17. Dieng MT, Sy MH, Diop BM, Niang SO, Ndiaye B: Mycetoma: 130 cases.

    Ann Dermatol Venereol 2003, 130:16-19. PubMed Abstract | Publisher Full Text OpenURL

  18. Lichon V, Khachemoune A: Mycetoma.

    Am J Clin Dermatol 2006, 7:315-321. PubMed Abstract | Publisher Full Text OpenURL

  19. Edwards KJ, Logan JMJ, Langham S, Swift C, Gharbia S: Utility of real-time amplification of selected 16S rRNA gene sequences as a tool for detection and identification of microbial signatures directly from clinical samples.

    J Med Microbiol 2012, 61:645-652. PubMed Abstract | Publisher Full Text OpenURL

  20. Welsh O, Sauceda E, Gonzales J, Ocampo J: Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic- mycetoma.

    J Am Acad Dermatol 1987, 17:443-448. PubMed Abstract | Publisher Full Text OpenURL

  21. Ameen M, Arenas R: Developments in the management of mycetomas.

    Clin Exp Dermatol 2008, 34:1-7. OpenURL

  22. Abd Bagi ME, Fahal AH, El Sheik H, Abdul Wahab O, Taifoor MK, Osmanr EM: Pathological fractures in mycetoma.

    Trans R Soc Trop Med Hyg 2003, 97:582-584. PubMed Abstract | Publisher Full Text OpenURL

  23. Khoo TK, Rekhraj IR: Mycetoma pedis (Maduramycosis) in an Indian in Singapore.

    Singapore Med J 1967, 8:269-270. PubMed Abstract OpenURL

  24. Geh GS: A case of madura foot successfully treated with large doses of intravenous crystalline penicillin.

    Med J Malaya 1969, 24:147-150. PubMed Abstract OpenURL

  25. Kutty MK, Bau K: Maduramycosis in a Chinese in West Malaysia.

    Med J Malaya 1969, 24:151-153. PubMed Abstract OpenURL

  26. Soo-Hoo TS, David CV: The first reported case of mycetoma caused by Streptomyces somaliensis in Malaysia.

    Aust J Derm 1982, 23:87-89. Publisher Full Text OpenURL

  27. Simuangco SA, Bocobo FC, Lacuna L: Review of literature on medical mycology in the Philippines, 1955–1962.

    Mycopathol Mycol Appl 1963, 20:145-156. PubMed Abstract | Publisher Full Text OpenURL

  28. Reyes AC, Tangco AF, Punsalang AP Jr: Maduromycosis (maduromycotic mycetoma) in the Philippines caused by Madurella grisea.

    Southeast Asian J Trop Med Public Health 1971, 2:17-21. PubMed Abstract OpenURL

  29. de Hoog GS, van Diepeningen AD, Mahgoub e-S, van de Sande WW: New species of Madurella, causative agents of black-grain mycetoma.

    J Clin Microbiol 2012, 50:988-994. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  30. Harahap M, Nasution MA: Dermatomycoses in Indonesia.

    Int J Dermatol 1984, 23:273-274. PubMed Abstract | Publisher Full Text OpenURL

  31. Andre M, Brumpt V, Destombes P, Segretain G: Fungal mycetoma with black grains due to Pyrenochaeta romeroi in Cambodia.

    Bull Soc Pathol Exot Filiales 1968, 61:108-112. PubMed Abstract OpenURL

  32. Tournier Lasserve C, Sun SK, Despruniee J: Osseous mycosis caused by mycetoma with black granules in Cambodia.

    Med Trop 1965, 25:646-648. OpenURL

  33. Kotrajaras R: Mycetoma, a review of seventeen cases seen at the Institute of Dermatology, Bangkok, Thailand.

    J Dermatol 1981, 8:133-137. PubMed Abstract OpenURL

  34. Mahaisavariya P, Chaiprasert A, Sivayathorn A, Khemngern S: Deep fungal and higher bacterial skin infections in Thailand: clinical manifestations and treatment regimens.

    Int J Dermatol 1999, 38:279-284. PubMed Abstract | Publisher Full Text OpenURL

  35. Freland C, Fur JL, Nemirovsky-Trebucq B, Lelong P, Boiron P: Primary cutaneous nocardiosis caused by Nocardia otitidiscaviarum: two cases and a review of the literature.

    J Trop Med Hyg 1995, 98:395-403. PubMed Abstract OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/12/349/prepub